期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

利奈唑胺致慢性肾脏病患者转氨酶升高、血小板减少、乳酸酸中毒一例并文献复习 被引量：7

Linezolid induced elevated transaminases,thrombocytopenia and lactic acidosis in a CKD patient:a case report and literature review
下载PDF
导出
摘要 1例终末期肾脏病患者,使用利奈唑胺后出现转氨酶升高、血小板减少和乳酸酸中毒并发症,停药后病情得到缓解。本文通过对该病例资料进行分析,提示慢性肾脏病患者使用利奈唑胺时,需要密切监测患者临床症状及相关实验室检查。利奈唑胺在该人群中应用的安全性和耐受性需要临床进一步验证。 A patient with end-stage renal disease,had the symptom of elevated transaminases,thrombocytopenia and lactic acidosis after linezolid therapy.The author analyzed the case,and suggested that both symptoms and laboratory tests should be monitored after linezolid was given.Further studies were needed to elucidate the safety and tolerability of linezolid in chronic kidney disease patients.
作者 赵新菊 王梅
机构地区 北京大学人民医院肾内科
出处 《实用药物与临床》 CAS 2012年第10期665-668,共4页 Practical Pharmacy and Clinical Remedies
关键词 利奈唑胺 慢性肾脏病 安全性 耐受性 Linezolid Chronic kidney disease Safety Tolerability
分类号 R692.5 [医药卫生—泌尿科学] R595.3 [医药卫生—内科学]
  • 相关文献

参考文献40

  • 1Gary French. Safety and tolerability of linezolid[ J]. Journal ofAntimicrobial Chemotherapy, 2003,51( Suppl) :45-53.
  • 2曲俊兵.利奈唑胺的研究进展[J].中国药业,2010,19(1):60-61. 被引量：32
  • 3Zhang QL, Rothenbacher D. Prevalence of chronic kidney dis-ease in population-based studies: Systematic review[ J]. BMCPublic Health,2008,8:117.
  • 4National Kidney Foundation. K/DOQI clinical practice guide-lines for chronic kidney disease : evaluation,classification,andstratification[ J]. Am J Kidney Dis,2002,39:SI.
  • 5Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronickidney disease in the United States [ J]. JAMA,2007 , 298 :2038-2047.
  • 6Obrador GT, Pereira BJ, Kausz AT. Chronic kidney disease inthe United States : an underrecognized problem [ J]. SeminNephrol,2002,22 :441.
  • 7Chadban SJ, Briganti E, Kerr PG, et al. Prevalence of kidneydamage in australian adults: the aus diab kidney study [ J]. JAm Soc Nephrol ,2003 ,14 : SI 31 -SI 38.
  • 8Imai E,Horio M,Iseki K,et al. Prevalence of chronic kidneydisease (CKD) in the Japanese general population predictedby the MDRD equation modified by a Japanese coefficient[J]. Clin Exp Nephrol,2007,11 : 156-163.
  • 9Zhang L,Zhang P,Wang F,et al. Prevalence and factors asso-ciated with CKD: A population study from Beijing[ J]. Am JKidney Dis,2008,51:373-384.
  • 10Ishani A,Collins AJ,Herzog CA,et al. Septicemia,access andcardiovascular disease in dialysis patients : The USRDS Wave2 study [J]. Kidney Int,2005,68:311-318.

二级参考文献35

共引文献83

同被引文献74

  • 1Yukihiko Kawasaki. The pathogenesis and treatment ofpediatric Henoch-Schonlein purpura nephritis [J]. Clin ExpNephrol, 2011,15(5):648-657.
  • 2Mills J A, Michel B A,Bloch DA, et al. The Americancollege of rheumatology 1990 critera for the classification ofHenoch-Schonlein purpura [J]. A rthritis Rheum, 1990,33?8):1114-1121.
  • 3Guissa V R, Aragao P A, Marques H H, et al. Chronicactive Epstein-Barr virus infection mimicking Henoch-Schonleinpurpura [J]. Acta Reumatol Port, 2010,35(5) ;513-517.
  • 4Schuetz P, Batschwaroff M, Dusemund F, et al. Effectivenessof a procalcitonin algorithm to guide antibiotic therapy inrespiratory tract infections outside of study conditions : a post-study survey [J]. Eur J Clin Microbiol Infect Dis, 2010,29(3):269-277.
  • 5Wakaki H, Ishikura K,Hataya H, et al. Henoch-Schonleinpurpura nephritis with nephrotic state in children : predictors ofpoor outcomes [J]. Pediatr Nephrol, 2011,26(6) ; 921-925.
  • 6Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey [J]. Clin Infect Dis, 2006,43 ( 2 ) : 180-187.
  • 7Garazzino S, De Rosa FG, Bargiacchi O, et al. Haematological safety of long-term therapy with linezolid [ J ]. Int J Antimicrob Agents,2007,29 (4) :471.
  • 8Niwa T, Suzuki A, Sakakibara S, et al. Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy [ J ], Clin Ther, 2009,31 ( 10 ) : 2126-2133.
  • 9Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression [J]. JAMA ,2001,285 (10) : 1291.
  • 10Azamfirei L, Copotoiu SM, Branzaniuc K, et al. Complete blindness after optic neuropathy induced by short-term linezolid treatment in a patient suffering from muscle dys-trophy[ J]. Pharmacoepidemiol Drug Saf,2007.16 (4) :402.

引证文献7

二级引证文献65

实用药物与临床
2012年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部